The Development of Kidney Stones in Postmenopausal Women Who Receive Estrogen Therapy
One of the JAMA/Achieves journals reported in the October 11 issue that there is association between increased risks of growing kidney stones in postmenopausal women with the usage of estrogen therapy.
The finding in healthy postmenopausal women indicate that estrogen therapy increase the risk of kidney stones. Conforming to background information in the study, between 5 -7 percent in the U.S is in view of the sizeable prevalence of kidney stones in this segment of the population.
Carried out by Dr. Naim M. Maalouf and colleagues, of the University of Texas Southwestern Medical Center at Dallas, the research start from the data collection of two trials escorted in the United States on postmenopausal women in the Women’s Health Initiative study.
The data was collected for an average of 7.1 years in the estrogen-only trial and 5.6 years for the estrogen plus progestin trial.
The researchers found that a total of 335 cases of kidney stones among hysterectomy of 10,739 postmenopausal women who received each an estrogen-only treatment or matching placebo, while 284 cases found among non hysterectomy of 16,608 postmenopausal women who received either an estrogen plus progestin treatment or matching placebo.
Unfortunately, the reason of the development risk of kidney stones is associated with estrogen therapy is still not discovered, however the findings could be beneficial to postmenopausal women whether they decide to take the prescription estrogen.
There is not significant link between the finding and age, BMI, ethnicity, coffee consumption, previous hormone treatment or the use of thiazide diuretics.
Related Post :
"